cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.3886/e198325v1
title: Data and Code for: Motivated Optimism and Workplace Risk

description: This project examines whether people engage in motivated optimism in the face of impending risk. It reports results from an online survey of U.S. workers returning back to work during the early months of the COVID-19 pandemic.<br><br>
description: The target group for our survey are working individuals in the U.S. who were furloughed or working from home at the time of the survey. A pre-screening survey administered by Lucid made sure that only qualified individuals were admitted who specified that they (1) ``worked outside the home before and working from home now (or furloughed)'', and (2) ``have no choice but to return to the workplace.'' Those who reported working from home before, were unemployed, or continued to work outside their homes during the pandemic did not qualify. Similarly, individuals who thought they would have a choice to decide on when to return to the workplace, who thought they may not return to the workplace, or who had the option to continue working from home also did not qualify. These requirements guarantee that our respondents are not yet back to their workplaces at the time we surveyed them, and that they will have to return to their workplaces at some point in the future. Therefore, the survey only includes people who are staying at home at the time they are surveyed and expect to be returning to their workplaces when called back. Our survey also included employment status verification and attention checks at the beginning to disqualify any remaining respondents who were not eligible to participate or were not paying sufficient attention to the survey questions. Of the 3,904 respondents who qualified, 6 reported invalid zip-codes and 21 had already tested positive for COVID-19, and are therefore excluded from the analysis.
DOI: 10.3886/e198325v2
title: Data and Code for: Motivated Optimism and Workplace Risk

description: This project examines whether people engage in motivated optimism in the face of impending risk. It reports results from an online survey of U.S. workers returning back to work during the early months of the COVID-19 pandemic.<br><br>
description: The target group for our survey are working individuals in the U.S. who were furloughed or working from home at the time of the survey. A pre-screening survey administered by Lucid made sure that only qualified individuals were admitted who specified that they (1) ``worked outside the home before and working from home now (or furloughed)'', and (2) ``have no choice but to return to the workplace.'' Those who reported working from home before, were unemployed, or continued to work outside their homes during the pandemic did not qualify. Similarly, individuals who thought they would have a choice to decide on when to return to the workplace, who thought they may not return to the workplace, or who had the option to continue working from home also did not qualify. These requirements guarantee that our respondents are not yet back to their workplaces at the time we surveyed them, and that they will have to return to their workplaces at some point in the future. Therefore, the survey only includes people who are staying at home at the time they are surveyed and expect to be returning to their workplaces when called back. Our survey also included employment status verification and attention checks at the beginning to disqualify any remaining respondents who were not eligible to participate or were not paying sufficient attention to the survey questions. Of the 3,904 respondents who qualified, 6 reported invalid zip-codes and 21 had already tested positive for COVID-19, and are therefore excluded from the analysis.
DOI: 10.3886/e198325v3
title: Data and Code for: Motivated Optimism and Workplace Risk

description: This project examines whether people engage in motivated optimism in the face of impending risk. It reports results from an online survey of U.S. workers returning back to work during the early months of the COVID-19 pandemic.<br><br>
description: The target group for our survey are working individuals in the U.S. who were furloughed or working from home at the time of the survey. A pre-screening survey administered by Lucid made sure that only qualified individuals were admitted who specified that they (1) ``worked outside the home before and working from home now (or furloughed)'', and (2) ``have no choice but to return to the workplace.'' Those who reported working from home before, were unemployed, or continued to work outside their homes during the pandemic did not qualify. Similarly, individuals who thought they would have a choice to decide on when to return to the workplace, who thought they may not return to the workplace, or who had the option to continue working from home also did not qualify. These requirements guarantee that our respondents are not yet back to their workplaces at the time we surveyed them, and that they will have to return to their workplaces at some point in the future. Therefore, the survey only includes people who are staying at home at the time they are surveyed and expect to be returning to their workplaces when called back. Our survey also included employment status verification and attention checks at the beginning to disqualify any remaining respondents who were not eligible to participate or were not paying sufficient attention to the survey questions. Of the 3,904 respondents who qualified, 6 reported invalid zip-codes and 21 had already tested positive for COVID-19, and are therefore excluded from the analysis.
DOI: 10.15468/dl.ptbjyx
title: Occurrence Download

description: A dataset containing 18 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Quercus camusiae Trel. ex Hickel & A.Camus"
 ]
}

 The dataset includes 18 records from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091985-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.xn4gsb
title: Occurrence Download

description: A dataset containing 1058 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Crataegus maximowiczii C.K.Schneid."
 ]
}

 The dataset includes 1058 records from 69 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091986-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.x9szzj
title: Occurrence Download

description: A dataset containing 103 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Rhododendron hirtipes Tagg"
 ]
}

 The dataset includes 103 records from 18 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091988-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.855jpd
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Ranunculus procurrentidens (Markl. ex Fagerstr.) Ericsson"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091989-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.ry47mf
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Allium flavescens Besser",
 "HasCoordinate is true",
 "Country is Iceland",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 2000",
 "CoordinateUncertaintyInMeters is less than 10000"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091990-240321170329656/datasets/export for details.
DOI: 10.15468/dl.h8ks6r
title: Occurrence Download

description: A dataset containing 93 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Salix integra Thunb.",
 "Country is China",
 "Year is greater than or equal to 1900",
 "HasCoordinate is true"
 ]
}

 The dataset includes 93 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091991-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.vr3jaz
title: Occurrence Download

description: A dataset containing 60 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Rhamnus hupehensis C.K.Schneid."
 ]
}

 The dataset includes 60 records from 13 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091992-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.hfv4wv
title: Occurrence Download

description: A dataset containing 18 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Rhododendron hirtolepidotum J.J.Sm."
 ]
}

 The dataset includes 18 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091995-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.7mcvap
title: Occurrence Download

description: A dataset containing 0 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Allium flavum L.",
 "HasCoordinate is true",
 "Country is Iceland",
 "HasGeospatialIssue is false",
 "Year is greater than or equal to 2000",
 "CoordinateUncertaintyInMeters is less than 10000"
 ]
}

 The dataset includes 0 records from 0 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091999-240321170329656/datasets/export for details.
DOI: 10.15468/dl.wza728
title: Occurrence Download

description: A dataset containing 9 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Ranunculus procurrentiformis (Julin) Ericsson"
 ]
}

 The dataset includes 9 records from 6 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091996-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.vmfzmn
title: Occurrence Download

description: A dataset containing 1008855 species occurrences available in GBIF matching the query:
{
 "TaxonKey" : [
 "is Corylus avellana L."
 ]
}

 The dataset includes 1008855 records from 3485 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0091958-240321170329656/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.7277/jr9w-fa74
title: Induced Partial Saturation (LPS) Through Transport and Reactivity for Liquefaction Mitigation (NEES-2011-1081)

description: &lt;p&gt;&lt;strong&gt;Title:&lt;/strong&gt; Induced Partial Saturation (LPS) Through Transport and Reactivity for Liquefaction Mitigation (NEES-2011-1081)&lt;/p&gt; &lt;p&gt;&lt;b&gt;Year Of Curation: &lt;/b&gt;2015&lt;/p&gt; &lt;p&gt;&lt;b&gt;Description: &lt;/b&gt;Devastating effects of ground failure, due to liquefaction of water saturated sands, on the built environment has been widely observed during most moderate to large size earthquakes. There is an urgent need to develop a cost effective liquefaction prevention method that can be applied to new sites as well as sites with existing structures. Researchers at Northeastern University, the University of Texas at Austin, Boise State University, the University of California at Santa Barbara, the University at Buffalo and the USGS will collaborate to develop an innovative and practical field technique for liquefaction mitigation by inducing partial saturation (IPS) in otherwise fully saturated liquefiable sands. The goals of this research are twofold: 1) to conduct fundamental research exploring the feasibility of inducing partial saturation under field conditions, by injecting very low concentration of sodium percarbonate solution, and through transport and reactivity slowly generate oxygen gas bubbles in sands; and, 2) to demonstrate the effectiveness of IPS in preventing the occurrence of liquefaction. The research will take advantage of unique experimental and field facilities of NSF&#39;s Network for Earthquake Engineering Simulation (NEES) to acquire fundamental knowledge on the behavior of partially saturated sands and to develop enabling technologies to verify the effectiveness of IPS as a liquefaction prevention method. The research program will achieve its goal by integrating small- and large-scale laboratory investigations, field tests and numerical simulation. NEES facilities to be utilized are the 1-g laminar box at NEES@Buffalo, the T-Rex shaker at NEES@Utexas and the wildlife field site at NEES@UCSB. &lt;/p&gt; &lt;p&gt;&lt;b&gt;Award: &lt;/b&gt;http://www.nsf.gov/awardsearch/showAward?AWD_ID=1134940&lt;/p&gt; &lt;p&gt;&lt;b&gt;PIs &amp; CoPIs: &lt;/b&gt;Mishac Yegian, Kenneth H. Stokoe, Sabanayagam Thevanayagam&lt;/p&gt; &lt;p&gt;&lt;b&gt;Dates: &lt;/b&gt;October 01, 2011 - September 30, 2014&lt;/p&gt; &lt;p&gt;&lt;b&gt;Organizations: &lt;/b&gt;&lt;br /&gt; Boise State University, ID, United States,&lt;br /&gt; Northeastern University, MA, United States,&lt;br /&gt; University of California, Santa Barbara, CA, United States,&lt;br /&gt; University of Texas at Austin, TX, United States&lt;/p&gt; &lt;p&gt;&lt;b&gt;Facilities: &lt;/b&gt;State University of New York at Buffalo, NY, United States,    University of Texas at Austin, TX, United States&lt;/p&gt; &lt;p&gt;&lt;b&gt;Sponsor: &lt;/b&gt;NSF - n/a - 1134940 &lt;/p&gt; &lt;p&gt;&lt;b&gt;Keywords: -- &lt;/b&gt;&lt;/p&gt; &lt;p&gt;&lt;b&gt;Publications: --&lt;/b&gt;&lt;/p&gt; &lt;nb:citations&gt;&lt;/nb:citations&gt;
DOI: 10.5281/zenodo.4543692
title: Dataset related to article "Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience"

description: This record contains raw data related to article “Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience" <strong>Background: </strong>Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited. <strong>Objectives: </strong>To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting. <strong>Methods: </strong>This observational, retrospective study enrolled adult patients (≥18 years) with moderate-to-severe plaque-type psoriasis who underwent 24 weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded. <strong>Results: </strong>Seventy-eight patients (mean age 47.9 years, 71.8% male, average disease duration 16.8 years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4 weeks of treatment, decreasing further at weeks 12 and 24 (all P &lt; 0.0001 vs. baseline). A higher number of cardiometabolic comorbidities and previous therapies were negatively associated with the achievement of PASI 90 at all assessments. Brodalumab was effective in bio-experienced patients, including those who had failed on anti-interleukin (IL)-17 therapies. Quality of life and patient satisfaction increased significantly during treatment (P &lt; 0.0001 and P &lt; 0.01 vs. baseline, respectively). Treatment was interrupted in 9 (11.5%) patients due to adverse events (n = 4), lack of efficacy (n = 3), lost to follow-up (n = 1) and surgical procedure (n = 1). <strong>Conclusions: </strong>Brodalumab is effective and safe in the treatment of moderate-to-severe psoriasis in a real-world setting, including in patients with failure to anti-IL17 therapies.
DOI: 10.5281/zenodo.4543691
title: Dataset related to article "Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience"

description: This record contains raw data related to article “Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience" <strong>Background: </strong>Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited. <strong>Objectives: </strong>To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting. <strong>Methods: </strong>This observational, retrospective study enrolled adult patients (≥18 years) with moderate-to-severe plaque-type psoriasis who underwent 24 weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded. <strong>Results: </strong>Seventy-eight patients (mean age 47.9 years, 71.8% male, average disease duration 16.8 years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4 weeks of treatment, decreasing further at weeks 12 and 24 (all P &lt; 0.0001 vs. baseline). A higher number of cardiometabolic comorbidities and previous therapies were negatively associated with the achievement of PASI 90 at all assessments. Brodalumab was effective in bio-experienced patients, including those who had failed on anti-interleukin (IL)-17 therapies. Quality of life and patient satisfaction increased significantly during treatment (P &lt; 0.0001 and P &lt; 0.01 vs. baseline, respectively). Treatment was interrupted in 9 (11.5%) patients due to adverse events (n = 4), lack of efficacy (n = 3), lost to follow-up (n = 1) and surgical procedure (n = 1). <strong>Conclusions: </strong>Brodalumab is effective and safe in the treatment of moderate-to-severe psoriasis in a real-world setting, including in patients with failure to anti-IL17 therapies.
DOI: 10.5281/zenodo.4543682
title: Dataset related to article "Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience"

description: This record contains raw data related to article “Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience" <strong>Introduction: </strong>Whether biologic therapies enhance the risk of coronavirus 2019 (COVID-19) or affect the disease outcome in patients with chronic plaque psoriasis remains to be ascertained. <strong>Objective: </strong>We sought to investigate the incidence of hospitalization and death for COVID-19 in a large sample of patients with plaque psoriasis receiving biologic therapies compared with the general population. <strong>Methods: </strong>This is a retrospective multicenter cohort study including patients with chronic plaque psoriasis (n = 6501) being treated with biologic therapy and regularly followed up at the divisions of dermatology of several main hospitals in the Northern Italian cities of Verona, Padua, Vicenza, Modena, Bologna, Piacenza, Turin, and Milan. Incidence rates of hospitalization and death per 10,000 person-months with exact mid-p 95% CIs and standardized incidence ratios were estimated in the patients with psoriasis and compared with those in the general population in the same geographic areas. <strong>Results: </strong>The incidence rate of hospitalization for COVID-19 was 11.7 (95% CI, 7.2-18.1) per 10,000 person-months in patients with psoriasis and 14.4 (95% CI, 14.3-14.5) in the general population; the incidence rate of death from COVID-19 was 1.3 (95% CI, 0.2-4.3) and 4.7 (95% CI, 4.6-4.7) in patients with psoriasis and the general population, respectively. The standardized incidence ratio of hospitalization and death in patients with psoriasis compared with those in the general population was 0.94 (95% CI, 0.57-1.45; P = .82) and 0.42 (95% CI, 0.07-1.38; P = .19), respectively. <strong>Conclusions: </strong>Our data did not show any adverse impact of biologics on COVID-19 outcome in patients with psoriasis. We would not advise biologic discontinuation in patients on treatment since more than 6 months and not infected with severe acute respiratory syndrome coronavirus 2 to prevent hospitalization and death from COVID-19.
DOI: 10.5281/zenodo.4543681
title: Dataset related to article "Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience"

description: This record contains raw data related to article “Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: a Northern Italy experience" <strong>Introduction: </strong>Whether biologic therapies enhance the risk of coronavirus 2019 (COVID-19) or affect the disease outcome in patients with chronic plaque psoriasis remains to be ascertained. <strong>Objective: </strong>We sought to investigate the incidence of hospitalization and death for COVID-19 in a large sample of patients with plaque psoriasis receiving biologic therapies compared with the general population. <strong>Methods: </strong>This is a retrospective multicenter cohort study including patients with chronic plaque psoriasis (n = 6501) being treated with biologic therapy and regularly followed up at the divisions of dermatology of several main hospitals in the Northern Italian cities of Verona, Padua, Vicenza, Modena, Bologna, Piacenza, Turin, and Milan. Incidence rates of hospitalization and death per 10,000 person-months with exact mid-p 95% CIs and standardized incidence ratios were estimated in the patients with psoriasis and compared with those in the general population in the same geographic areas. <strong>Results: </strong>The incidence rate of hospitalization for COVID-19 was 11.7 (95% CI, 7.2-18.1) per 10,000 person-months in patients with psoriasis and 14.4 (95% CI, 14.3-14.5) in the general population; the incidence rate of death from COVID-19 was 1.3 (95% CI, 0.2-4.3) and 4.7 (95% CI, 4.6-4.7) in patients with psoriasis and the general population, respectively. The standardized incidence ratio of hospitalization and death in patients with psoriasis compared with those in the general population was 0.94 (95% CI, 0.57-1.45; P = .82) and 0.42 (95% CI, 0.07-1.38; P = .19), respectively. <strong>Conclusions: </strong>Our data did not show any adverse impact of biologics on COVID-19 outcome in patients with psoriasis. We would not advise biologic discontinuation in patients on treatment since more than 6 months and not infected with severe acute respiratory syndrome coronavirus 2 to prevent hospitalization and death from COVID-19.